These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 21117029)

  • 1. A useful immunohistochemical approach to evaluate intraductal proliferative lesions of the breast and to predict their prognosis.
    Omi Y; Yamamoto T; Okamoto T; Obara T; Kobayashi M
    Histol Histopathol; 2011 Jan; 26(1):79-86. PubMed ID: 21117029
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Myoepithelial cells in solid variant of intraductal papillary carcinoma of the breast: a potential diagnostic pitfall and a proposal of an immunohistochemical panel in the differential diagnosis with intraductal papilloma with usual ductal hyperplasia.
    Moritani S; Ichihara S; Kushima R; Okabe H; Bamba M; Kobayashi TK; Hattori T
    Virchows Arch; 2007 May; 450(5):539-47. PubMed ID: 17377808
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Estrogen Receptor and Cytokeratin 5 Are Reliable Markers to Separate Usual Ductal Hyperplasia From Atypical Ductal Hyperplasia and Low-Grade Ductal Carcinoma In Situ.
    Martinez AP; Cohen C; Hanley KZ; Li XB
    Arch Pathol Lab Med; 2016 Jul; 140(7):686-9. PubMed ID: 27116088
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Value of CK5/6, CK14, ER and PR detection in differential diagnosis of intraductal proliferative lesions of the breast].
    Niu F; Wang L; Zhang W; Lyu S; Niu Y
    Zhonghua Zhong Liu Za Zhi; 2015 Oct; 37(10):749-52. PubMed ID: 26813593
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Clinicopathologic and immunohistochemical study of 187 cases of intraductal papillary neoplasm of breast].
    Zhang H; Xiong Y; Zhang S; Zhang Y; Wang YH; Li T
    Zhonghua Bing Li Xue Za Zhi; 2011 Nov; 40(11):726-31. PubMed ID: 22336153
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Solid papillary ductal carcinoma in situ versus usual ductal hyperplasia in the breast: a potentially difficult distinction resolved by cytokeratin 5/6.
    Rabban JT; Koerner FC; Lerwill MF
    Hum Pathol; 2006 Jul; 37(7):787-93. PubMed ID: 16784976
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Double immunostaining with p63 and high-molecular-weight cytokeratins distinguishes borderline papillary lesions of the breast.
    Ichihara S; Fujimoto T; Hashimoto K; Moritani S; Hasegawa M; Yokoi T
    Pathol Int; 2007 Mar; 57(3):126-32. PubMed ID: 17295644
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Role of cytokeratin expression in differential diagnosis of intraductal proliferative lesions of breast].
    Zhang JL; Zhang HY; Wei B; Lang ZQ; Bu H
    Zhonghua Bing Li Xue Za Zhi; 2004 Aug; 33(4):316-9. PubMed ID: 15363314
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression pattern and methylation of estrogen receptor α in breast intraductal proliferative lesions.
    Mao X; Qiao Z; Fan C; Guo A; Yu X; Jin F
    Oncol Rep; 2016 Oct; 36(4):1868-74. PubMed ID: 27498697
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of immunohistochemistry for smooth-muscle actin, p63, CD10 and cytokeratin 14 in the differential diagnosis of papillary lesions of the breast.
    Tse GM; Tan PH; Lui PC; Gilks CB; Poon CS; Ma TK; Law BK; Lam WW
    J Clin Pathol; 2007 Mar; 60(3):315-20. PubMed ID: 16698948
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of CD56 and CD57 immunostainings for discrimination between endocrine ductal carcinoma in situ and intraductal papilloma.
    Tajima S; Maeda I; Kanemaki Y; Nakajima Y; Tatsunami S; Fukuda M; Takagi M
    Pathol Int; 2010 Jun; 60(6):459-65. PubMed ID: 20518901
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytokeratins in papillary lesions of the breast: is there a role in distinguishing intraductal papilloma from papillary ductal carcinoma in situ?
    Tan PH; Aw MY; Yip G; Bay BH; Sii LH; Murugaya S; Tse GM
    Am J Surg Pathol; 2005 May; 29(5):625-32. PubMed ID: 15832086
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Papillary lesions of the breast].
    Ni YB; Tse GM
    Zhonghua Bing Li Xue Za Zhi; 2013 Nov; 42(11):721-6. PubMed ID: 24447546
    [No Abstract]   [Full Text] [Related]  

  • 14. [Clinicopathologic study of breast cancer with features of endocrine ductal carcinoma-in-situ].
    Yang WT; Xu YX; Zhang TQ
    Zhonghua Bing Li Xue Za Zhi; 2006 Oct; 35(10):594-7. PubMed ID: 17134566
    [TBL] [Abstract][Full Text] [Related]  

  • 15. D2-40: an additional marker for myoepithelial cells of breast and the precaution in interpreting tumor lymphovascular invasion.
    Ren S; Abuel-Haija M; Khurana JS; Zhang X
    Int J Clin Exp Pathol; 2011 Jan; 4(2):175-82. PubMed ID: 21326813
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined evaluation of CK5/6, ER, p63, and MUC3 for distinguishing breast intraductal papilloma from ductal carcinoma in situ.
    Furuya C; Kawano H; Yamanouchi T; Oga A; Ueda J; Takahashi M
    Pathol Int; 2012 Jun; 62(6):381-90. PubMed ID: 22612506
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ductal carcinoma in situ with spindle cells: a potential diagnostic pitfall in the evaluation of breast lesions.
    Tan PH; Lui GG; Chiang G; Yap WM; Poh WT; Bay BH
    Histopathology; 2004 Oct; 45(4):343-51. PubMed ID: 15469472
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of the progression of intraductal proliferative lesions in the breast by PCR-based clonal assay.
    Yu Q; Niu Y; Yu Y; Ding X; Shi Y
    Breast Cancer Res Treat; 2009 Apr; 114(3):433-40. PubMed ID: 18425676
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of high-grade ductal carcinoma in situ with and without regressive changes: diagnostic and biologic implications.
    Chivukula M; Domfeh A; Carter G; Tseng G; Dabbs DJ
    Appl Immunohistochem Mol Morphol; 2009 Dec; 17(6):495-9. PubMed ID: 19407654
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunohistochemical staining of papillary breast lesions.
    Troxell ML; Masek M; Sibley RK
    Appl Immunohistochem Mol Morphol; 2007 Jun; 15(2):145-53. PubMed ID: 17525625
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.